Mark Dunphy

Credentials: · · · ·

History

New York Presbyterian Hospital · Memorial Hospital for Cancer and allied Diseases
Present

HER2 PET Imaging to Assess HER2 Heterogeneity and Predict Response to HER2-Targeted Therapy in Biliary Tract Cancer
National Cancer Institute · R01
PI · $715K · Sloan-Kettering Inst Can Research
2026–2031
[18F]-PU-AD Epichaperome PET Imaging Probe
National Institute on Aging · RF1
PI · $4.8M · Sloan-Kettering Inst Can Research
2022–2027
Biomarkers for Predicting Response to Hsp90 Therapy
National Cancer Institute · R01
PI · $2.9M · Sloan-Kettering Inst Can Research
2013–2019
First Human Trial of Src/Abl-Targeted PET Tumor Imaging with F-18 SKI-249380
National Cancer Institute · R21
Contact PI · $736.3K · Sloan-Kettering Inst Can Research
2012–2016

PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
Principal investigator · Recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2019–2027
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2013–2020
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2012–2026
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Principal investigator · Active not recruiting · Early phase 1
Memorial Sloan Kettering Cancer Center
2010–2026